MFN2 and metabolic dysfunction-associated steatotic liver disease: Studies have shown that the expression of Mfn2 is significantly reduced in liver tissues of patients with nonalcoholic fatty liver disease and mouse models, and specific knockout of Mfn2 from liver cells, the levels of inflammatory factors, and triglycerides in mice increased significantly, promoting the occurrence and development of liver fibrosis and liver cancer.